VivoSeq
Oncology

Clear Cell Renal Carcinoma

31

Pipeline Programs↗

1

Active Trials↗

17

Companies Involved↗

Clear Cell Renal Carcinoma is a moderately active landscape with 31 programs across 17 companies. The most active players are AstraZeneca, Bayer, Merck & Co.. 8 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

52/100

Pipeline Velocity

0/100

Mech. Concentration

9/100

Completion Rate

83/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AstraZeneca logo

AstraZeneca

1 program

Phase 1Bayer logo

Bayer

1 program

Phase 1Merck & Co. logo

Merck & Co.

3 programs

Phase 2I

Iovance Biotherapeutics, Inc.

1 program

Phase 2S

Shanghai Pharmaceuticals Holding Co., Ltd

1 program

Phase 2Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

63%

Small molecule

19 of 30 classified programs — the dominant modality here.

37%ALL OTHERSMonoclonal antibody930%Protein / enzyme27%

Small molecule leads; the ring shows all 30 classified programs, each share of the total. Modality classified for 100% of 31 pipeline programs.

Analysis

Trial Status

8

clinical trials

Completed5 · 63%
Unknown status1 · 13%
Withdrawn1 · 13%
Active, not recruiting1 · 13%

Clinical Trials

Trial Activity

8 trials

Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma
Active, not recruiting·SSun Yat-sen University·Phase 2·NCT05220267·44 enrolled
Interleukin-2 With Sorafenib (BAY 43-9006) for Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma
Completed·OOhio State University Comprehensive Cancer Center·Phase 1·NCT00418496·17 enrolled
Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
Completed·IIdera Pharmaceuticals, Inc.·Phase 2·NCT00729053·92 enrolled
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00550277·20 enrolled
Bevacizumab (Avastin) and RAD001(Everolimus)in the Treatment of Advanced Clear Cell Renal Carcinoma
Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00323739·80 enrolled
Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
Completed·CCentral European Society for Anticancer Drug Research·Phase 2·NCT00979966·22 enrolled
Interferon Alpha-2b (Intron A) for Metastatic or Unresectable Clear Cell Renal Carcinoma
Withdrawn·OOhio State University Comprehensive Cancer Center·Phase 2·NCT00293527
Denosumab and Pembrolizumab in Clear Cell Renal Carcinoma
Unknown status·AAustralian and New Zealand Urogenital and Prostate Cancer Trials Group·Phase 2·NCT03280667·59 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)